Robinson M
University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA.
Int J Clin Pract. 2005 Jun;59(6):709-15. doi: 10.1111/j.1368-5031.2005.00517.x.
Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease. Proton pump inhibitors (PPIs) are the antisecretory drugs of choice for serious acid-related conditions. Ample recent data exist to explicate virtually every aspect of the clinical management of acid-peptic disorders with PPIs. Although all PPIs are effective, there are some differences in their clinical performance, particularly in terms of the degree and speed of gastric acid suppression. Rapid onset of acid suppression may be particularly relevant to newer approaches, such as 'on-demand' or intermittent therapy for non-erosive reflux disease and shorter regimens for Helicobacter pylori eradication. New data, in addition, highlight differences in PPI metabolism that may both affect efficacy and predispose patients to drug-drug interactions. PPI selection should involve the awareness of these issues.
胃酸在许多胃肠道疾病中具有致病性，如胃食管反流病和消化性溃疡病。质子泵抑制剂（PPIs）是治疗严重酸相关疾病的首选抗分泌药物。最近有大量数据几乎阐明了使用PPIs治疗酸相关性疾病临床管理的各个方面。虽然所有PPIs都有效，但它们的临床性能存在一些差异，特别是在胃酸抑制的程度和速度方面。快速起效的胃酸抑制可能与新的治疗方法特别相关，如对非糜烂性反流病的“按需”或间歇治疗以及较短疗程的幽门螺杆菌根除治疗。此外，新数据突出了PPIs代谢的差异，这可能既影响疗效又使患者易发生药物相互作用。选择PPIs时应了解这些问题。
